|Alliqua BioMedical, Inc.|
2150 Cabot Boulevard West
United States - Map
Alliqua BioMedical, Inc. provides wound care solutions. The company offers Extracellular Matrix, a suite of advanced wound management products; Biovance, a decellularized and dehydrated allograft for the management of non-infected partial-and full-thickness wounds; SilverSeal, a hydrogel wound dressing with silver coated fibers; and Hydress, an over-the-counter hydrogel wound dressing. It also provides contact dressings, island dressings, and wraps using TheraBond 3D antimicrobial barrier systems. In addition, the company offers Sorbion sachet S, a primary dressing for exudating wounds, such as surgical wounds, venous leg ulcers, and diabetic ulcers; Sorbion sana, a primary wound dressing that provides an another form of wound treatment; and products with hydrokinetic fibers as primary dressings. Further, it provides contract manufacturing services, including the development, manufacture, and market of high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company has a license, marketing, and development agreement with Anthrogenesis Corporation for the development and commercialization of Extracellular Matrix and Biovance products. Alliqua BioMedical, Inc. primarily serves medical device manufacturers through its direct sales force; and an independent network of agents. The company is headquartered in Langhorne, Pennsylvania.
|Mr. David Ian Johnson ,
Chief Exec. Officer, Pres, Director and Exec. Chairman of Aquamed Technologies Inc
|Mr. Brian M. Posner CPA, MBA.,
Chief Financial Officer, Principal Accounting Officer, Treasurer and Sec.
|Mr. Bradford C. Barton ,
Chief Operating Officer
|Ms. Lori Toner ,
Chief Marketing Officer
|Dr. Phillip D. Forman M.D., DPM,
Exec. VP of Clinical Affairs
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|